TRUFFLE-CAPITAL
8.7.2021 08:02:05 CEST | Business Wire | Press release
Created by the private equity firm Truffle Capital and the research and consulting firm teknowlogy | CXP-PAC, the Truffle 100 2021 provides an overview of the French software industry by analyzing the activity of the top 100 companies in the sector during 2020.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210707005107/en/
- This period was marked by several notable highlights: with a +6.6% increase, the growth in activity in the sector reached record highs, i.e. €11.6 billion; however, a record number of companies (33%) posted a fall in revenue.
- For the first time since 2013, the difference between the 50th and the 100th publishers decreased; but with 35% of the sector's revenue in 2020, the weighting of the company in first place continues to grow (+2 pts in 2020)
The Truffle 100 clearly shows that the anticipated market shock has not affected the whole software industry. Nevertheless, the companies have put forward a shared vision of the future of the market.
- The cloud is now considered by 92% of companies as the trend that will provide momentum in the sector over the coming years. This new trend, driven by the crisis, recorded a growth of +16 pts compared to the ranking published in 2020.
- In light of this situation, three-quarters of the companies plan to increase their workforce, and three-quarters also plan to ramp up their R&D projects.
Commenting on this 16th edition of Truffle 100, Cédric Ô, French Secretary of State for the Digital Economy, concluded: "In similar fashion to previous years, the development of the sector has been achieved by the long-standing efforts of its stakeholders and their capacity to anticipate the major technological breakthroughs which are, in the digital industry, more frequent and clearer to distinguish than in other industries ".
Bernard-Louis Roques, Managing Director and co-founder of Truffle Capital declared: "At a time when the ability to respond to events and the management of expertise proved vital, the French software industry played a civic role and created jobs on the domestic marke t".
Nadia Idrissi, Chairwoman of teknowlogy | CXP-PAC, added: "Highly topical themes such as the cloud, cybersecurity and the remote workplace have driven the market and allowed the majority of publishers, who are - on the whole - well prepared, to deliver revenue growth. [...] Companies using software solutions are picking up the pace of this forced march towards major digital transformation investments, and this also applies to industrial processes ".
The 16th edition of the Truffle 100 is available on the following website: https://www.truffle100.fr/
About Truffle Capital
Founded in 2001, Truffle Capital is an independent European venture capital company, specializing in life sciences (MedTech and Biotech) and breakthrough technologies in the IT sectors (FinTech and InsurTech). Truffle Capital’s mission is to support the creation and development of young innovative companies capable of becoming tomorrow’s leaders. The company is chaired by Patrick Kron and managed by Dr Philippe Pouletty and Bernard-Louis Roques, co-founders and General Managers. Truffle Capital manages €700 million in assets. Since its creation, it has raised nearly €1.1 billion and has supported over 75 companies in the digital technology and life sciences sectors. In 2019, Truffle Capital announced it had raised nearly €400 million in new institutional funds, including €140 million in Fintech/Insurtech.
Further information: www.truffle.com — Twitter: @trufflecapital
About teknowlogy Group
teknowlogy | CXP-PAC teknowlogy | CXP-PAC is the leading European independent analysis and consulting firm in the field of software, IT services and digital transformation. As a privileged partner of European user companies, it offers them assistance in defining their digital strategy, managing projects and reducing the risks linked to technological choices and their implementation.
Owing to its knowledge of market trends and user-company expectations, teknowlogy | CXP-PAC helps software publishers and ESNs to better establish, execute and promote their own strategy in line with market expectations and in anticipation of future needs.
Capitalizing on more than 40 years of experience, teknowlogy | CXP-PAC has a network of 50 experts based in Paris, Munich, Bucharest, and London.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210707005107/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release
Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom